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Adult onset Still’s disease (AOSD) is a rare systemic inflammatory disorder of unknown etiology. It is characterized by daily fevers,
arthralgias or arthritis, typical skin rash, and leukocytosis. Hepatic involvement is frequently observed in the course of AOSD with
mildly elevated transaminases and/or hepatomegaly. Fulminant hepatic failure, occasionally requiring urgent liver transplantation,
is a rare manifestation of AOSD. Here, we present a case of 22-year-old woman with no significant medical history who initially came
with fever, arthralgias, myalgias, generalized weakness, and sore throat. Laboratory data showed mildly elevated transaminases
and markedly elevated ferritin levels. She was diagnosed with AOSD based on Yamaguchi diagnostic criteria and was started on
prednisone. Three months later, while she was on tapering dose of steroid, she presented with fever, abdominal pain, jaundice, and
markedly elevated transaminases. Extensive workup excluded all potential causes of liver failure. She was diagnosed with AOSD
associated acute liver failure (ALF). Intravenous (IV) methylprednisolone pulse therapy was started, with dramatic improvement in
liver function. Our case demonstrated that ALF can present as a complication of AOSD and IV mega dose pulse methylprednisolone
therapy can be employed as a first-line treatment in AOSD associated ALF with favorable outcome.

1. Introduction
Adult onset Still’s disease (AOSD) is a rare systemic inflammatory disorder with a typical evanescent salmon-pink nonpruritic maculopapular rash, leukocytosis (≥10,000 WBC/
mm3 ) with at least 80% neutrophils, fever, and arthralgias/
arthritis [1]. Other common symptoms include sore throat,
myalgias, lymphadenopathy, hepatomegaly, splenomegaly,
and abdominal pain. Markedly elevated serum ferritin levels
have been frequently seen. AOSD is a clinical diagnosis and
several sets of classification criteria have been proposed to aid
in the diagnosis. The most widely validated criteria cited in
the literature are Yamaguchi’s criteria, with five or more criteria of which presence of two or more major criteria have a sensitivity and specificity of 96.2% and 92.1%, respectively [2].

Hepatic involvement is frequently observed in the course
of AOSD. Mild elevation in transaminases is common.
Acute liver failure (ALF) is a rare manifestation, occasionally
requiring urgent liver transplantation [3–9]. We report a case
of ALF in a patient with recently diagnosed AOSD who
was successfully treated with IV pulse methylprednisolone
therapy.

2. Case Report
A 22-year-old African American female with a past medical
history significant for AOSD presented with fever, arthritis, and abdominal pain. Three months ago, she presented
with fever, arthralgia, myalgias, generalized weakness, sore
throat, maculopapular skin rash, and cervical and axillary
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lymphadenopathy. Laboratory data showed mildly elevated
transaminases and markedly elevated ferritin levels. After
extensive work up including negative HIV and other acute
viral illness and normal bone marrow biopsy, patient was
diagnosed with AOSD based on Yamaguchi diagnostic criteria. She had met three major and four minor criteria.
She was discharged on prednisone 20 mg/day. Currently,
while on tapering dose of prednisone, she presented with
fever, arthritis, and abdominal pain. On examination, she
was slightly drowsy and was noted to have fever of 101.6∘ F,
mild conjunctival pallor, and icteric sclera. Her abdominal examination showed epigastric and right upper quadrant tenderness. Laboratory findings included normal basic
metabolic panel. Complete blood count showed leucocyte
count of 4.2 × 109 /L, hemoglobin 11.4 gm/dL, platelet count
144 × 109 /L. Liver function tests showed total bilirubin of
5.4 mg/dL, aspartate aminotransferase (AST) of 4,974 U/L,
alanine aminotransferase (ALT) of 2,522 U/L, alkaline phosphatase of 211 U/L, gamma glutamate transpeptidase (GGT)
of 155 U/L, and albumin of 3 g/dL. Coagulation studies were
prothrombin time (PT) of 18.1 seconds (151% of normal),
international normalised ratio (INR) of 1.53, and activated
partial thromboplastin time (APTT) of 29.1 seconds (116%
of normal). Serum ferritin level was >15,000 ng/mL (normal: 40–200 ng/mL). Serum and urine toxicology screen
was negative. Autoimmune workup including antinuclear
antibody, rheumatoid factor, anti-mitochondrial antibody,
anti-smooth muscle antibody, anti-liver/kidney microsomal
antibody, immunoglobulins, ceruloplasmin, and alpha 1
antitrypsin were all negative. Serology for viral hepatitis
A, hepatitis B, hepatitis C, hepatitis D, hepatitis E, herpes
simplex virus (HSV), Epstein-Barr virus, Cytomegalovirus,
human immunodeficiency virus (HIV), West Nile virus,
Leptospira, Borrelia, and Q fever were negative. Ultrasound of
the abdomen showed normal liver morphology with normal
echogenicity. She was diagnosed with ALF secondary to
AOSD. She was promptly started on IV pulse methylprednisolone therapy 1 gram/day for 3 days. After 3 days of
treatment with pulse methylprednisolone therapy, her liver
enzymes began to trend down dramatically. IV steroids were
then switched to peroral prednisone 40 mg/day. She was
discharged in a stable condition with near normal liver
function tests after 8 days of hospitalization. One year later,
she remained in remission on low dose prednisone.

3. Discussion
Still’s disease is named after George. F. Still, who originally
described 22 cases of chronic polyarthritis usually referred to
as juvenile rheumatoid arthritis in children in 1897. In 1971,
Eric Bywaters described 14 cases resembling Still’s disease
that started in adult life, hence the name adult onset Still’s
disease [10]. In a retrospective study of 62 patients in West
France, the estimated incidence of AOSD was 0.16 per 100000
inhabitants. Mean age of the study population was 36 [11].
Based on an epidemiological survey conducted in Japan,
estimated crude prevalence was calculated as 0.73 and 1.47
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per 100,000 population for males and females, respectively,
with a female to male ratio of 2 : 1 [12].
The etiology of AOSD remains unknown. AOSD is considered as multisystemic disorder in which several cytokines
including interleukin (IL), mainly IL-1, IL-6, and IL-18,
interferon (IFN) gamma, and tumor necrosis factor (TNF)
alpha have been implicated in the pathogenesis [1]. IL-18
has been identified to play a key role in AOSD pathogenesis
including high serum ferritin levels and liver injury in AOSD
[8].
Clinical course of AOSD is usually benign. Rarely,
serious complications such as ALF, macrophage activation
syndrome/hemophagocytic syndrome, pericarditis, cardiac
tamponade, disseminated intravascular coagulation, serous
peritonitis, pleuritis, and respiratory failure are seen [1]. Our
patient presented with ALF.
Hepatic involvement usually manifesting as asymptomatic elevation in transaminases with or without hepatomegaly is frequently seen in AOSD; indeed liver dysfunction is one of Yamaguchi’s minor criteria. ALF is a
rare complication of AOSD. ALF can occur at the time
of AOSD diagnosis, during tapering of immunosuppressive
therapy, or years after diagnosis when other symptoms of
AOSD are well controlled. After extensive review of literature,
seventeen cases of ALF in AOSD were reported [3–9, 13–21],
of which seven (41.1%) required liver transplantation [3–9].
Characteristics of previously published cases of ALF in AOSD
are highlighted in Table 1.
Of the seventeen cases reported, twelve patients (12/17
= 70.5%) are females, as our patient [3, 5, 7–9, 13–15, 17–
19]. Seven patients had AOSD diagnosed at the time of ALF
presentation (7/17 = 41.1%) [3, 9, 14, 15, 18–20]. Eight patients
(8/17 = 47%) had AOSD diagnosed prior to the onset of ALF
(timeline between AOSD diagnosis and onset of liver failure
ranging from 10 days to 3 years) [5–8, 13, 16, 17]. One patient
(1/17 = 5.88%) had AOSD diagnosed following liver transplantation for ALF when symptoms of the disease recurred
with tapering of oral steroids and in one patient (1/17 = 5.88%)
we were unable to obtain information regarding the timeline
of AOSD diagnosis and onset of ALF [4, 21]. Eight patients
(8/17 = 47%) were on steroids with or without combination
with other immunosuppressant drugs for the treatment of
AOSD prior to onset of ALF [5, 7, 8, 13, 14, 16, 17]. Of
the eight patients with prior AOSD diagnosis, four received
treatment with methylprednisolone pulse therapy for ALF
[5–8]. All four patients subsequently received liver transplantation and recovered with uneventful follow-up. Two patients
recovered with pulse dexamethasone therapy combined with
cyclosporine and one patient recovered with prednisolone
and anakinra without the need for liver transplantation [16,
17]. One patient was on prednisolone at the time of ALF and
went into grade IV hepatic encephalopathy the next day and
died [13]. Of the seven patients who were diagnosed with
AOSD simultaneously at the time of presentation with ALF,
two patients received therapy with pulse methylprednisolone;
of them, one patient recovered and the other required
liver transplant and died after transplantation from disseminated intravascular coagulation and intraventricular hemorrhage [9, 15]. Three patients were started on prednisolone
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Table 1: Characteristics of cases reported on ALF in Adult Onset Still’s Disease (AOSD).
Author
[Reference]
Liese et al.
[3]

Interval between
Gender/Age
AOSD diagnosis
(Years)
and ALF

Hepatotoxics
prior to the
onset of ALF

Baseline AOSD
treatment before
ALF

F/24

Simultaneous

None

None

Terán et al.
[4]

M/23

AOSD
diagnosed after
ALF when
symptoms
recurred

None

None

Taccone et al.
[5]

F/28

1 month

None

Prednisolone
8 mg/day

Mc Farlane
et al. [6]

M/21

<1 month

Acetaminophen

Aspirin,
Acetaminophen,

Yamanaka
et al. [7]

F/20

3 years

None

Cyclosporine,
Prednisolone
15 mg/day

Ogata et al.
[8]

F/20

3 years

None

Prednisolone
15 mg/day

Dino et al.
[9]

F/44

Simultaneous

Aspirin 1.8
gram/day

None

Thabah et al.
[13]

F/29

10 days

Indomethacin

Ott et al.
[14]

F/25

Simultaneous

None

Linde et al.
[15]

F/39

Simultaneous

Acetaminophen,
Ibuprofen

NSAIDs

Mylona et al.
[16]

M/46

2 months

None

Tapering dose of
Prednisolone

Indomethacin

Oral
betamethasone,
methotrexate and
Indomethacin

None

Prednisolone
50 mg/day and
Cyclosporine
150 mg/day

F/51

3 years

Nagashima
et al. [17]
F/32

2 weeks

PO Prednisolone
40 mg/day and
indomethacin
Prednisolone
16 mg/day for an
undetermined
rheumatic disease

Treatment of ALF
associated with
AOSD
Extracorporeal liver
support

Underwent
liver
transplantation

Outcome

Yes

Recovered

Supportive care

Yes

Recovered

Yes

Recovered

Yes

Recovered

Yes

Recovered

Yes

Recovered

Yes

Died

Steroids

No

Died

UDCA

No

Recovered

No

Recovered

No

Recovered

No

Recovered

No

Recovered

IV
Methylprednisolone
500 mg and MARS
IV one pulse of
Methyprednisolone
250 mg and then
20 mg IV BID
IV
Methylprednisolone
pulse 500 mg/day for
3 days
2 days of pulse IV
Methyl prednisolone
1 gm per day and
then plasma
exchange
IV
MethylPrednisolone
1 gm/day for 2 days

3 days of IV
Methyprednisolone
250 mg per day
Prednisolone
75 mg/day PO and
Anakinra
100 mg/day PO
IV Pulse
dexamethasone
100 mg/day and
Cyclosporine
120 mg/day
3 days of IV
dexamethasone
pulse therapy
120 mg/day,
dexamethasone
5 mg/day
cyclosporine
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Table 1: Continued.

Author
[Reference]
Hogan et al.
[18]
Takami et al.
[19]
Schuster et al.
[20]
Atsukawa
et al. [21]

Interval between
Gender/Age
AOSD diagnosis
(Years)
and ALF

Hepatotoxics
prior to the
onset of ALF

F/35

Simultaneous

None

F/74

Simultaneous

None

50 y

Simultaneous

None

34

NM

None

Baseline AOSD
treatment before
ALF

Treatment of ALF
Underwent
Outcome
associated with
liver
AOSD
transplantation
2 days of
Sulfasalazine for
Recovered
Methylprednisolone
No
rheumatic disease
80 mg IV every 8 hrs
Prednisolone
Recovered
None
No
30 mg/day
Prednisolone,
Recovered
None
No
methotrexate
Prednisolone
Recovered
None
No
40 mg/day

Gm/dL-grams/deciliter, IV-Intravenous, PO-peroral, MARS-Molecular Adsorbent Recirculating System, mg-milligrams, BID-twice a day, UDCAUrsodeoxycholic acid, NSAIDS-Non steroidal anti inflammatory drugs, hrs-hours, NM-Not mentioned.

(not pulse therapy) and all of them recovered [19–21]. One
patient was treated with ursodeoxycholic acid and recovered
[14]. One patient did not receive any steroids and underwent
liver transplantation [3].
Based on the above data it is evident that patients
with ALF who were simultaneously diagnosed with AOSD
responded to steroid therapy with or without combination
with other immunosuppressants (4 patients out of 7 patients,
57.14%) better than those who had prior diagnosis of AOSD
and were already on maintenance immunosuppressant therapy (3 patients out of 8, 37.5%) [15–20]. Also it is noted that
response to pulse steroid therapy decreases with increase in
the number of AOSD exacerbations presenting with ALF
[7, 8]. In our patient, this is the first exacerbation of AOSD
presenting with ALF for which we promptly started IV pulse
methylprednisolone with a good outcome. To our knowledge,
this is the first case reported in an African American female
patient with prior AOSD diagnosis presenting with ALF who
responded to IV pulse methylprednisolone without the need
for liver transplantation.
Liver biopsy findings in active AOSD are nonspecific
which can include periportal inflammatory infiltrates, Kupffer cell hyperplasia, periportal fibrosis, and focal hepatitis
with submassive or massive necrosis. The utility of liver
biopsy in the diagnosis of AOSD is undetermined. It may
be useful in identifying previously undiagnosed concomitant
liver diseases, which may be exacerbated by steroids and
immunosuppressive therapies for adult onset Still’s disease,
which can influence the management and eventual outcome
of liver injury in AOSD [22].
Liver dysfunction in AOSD often reflects underlying
disease activity [23]. Improvement in liver function occurs
concomitantly with recovery of AOSD flare following initiation of appropriate therapy. Steroids are usually employed
as the first-line agents for AOSD associated ALF. Intravenous methylprednisolone pulse therapy is recommended in
patients with acute multisystem flares involving vital organs
such as cardiac tamponade, pleuritis, respiratory failure,
ALF, severe anemia due to macrophage activation syndrome
(MAS), disseminated intravascular coagulation, and serous
peritonitis [24]. As described in our patient, remarkable

improvement in liver enzymes occurred following three
days of IV pulse methylprednisolone therapy (1 gram/day).
Steroid-refractory ALF cases secondary to AOSD have
showed response to treatment with cyclosporine and IL-1
receptor antagonist (anakinra) [16, 17]. Occasionally, ALF
persists despite aggressive medical therapy and expeditious
evaluation for liver transplantation is warranted under such
circumstances.
Our case demonstrated that ALF can be a rare presentation of AOSD in the absence of other potential causes
of liver failure. Prompt initiation of IV mega dose methylprednisolone pulse therapy may be indicated as a first-line
treatment in AOSD associated ALF with favorable outcome.
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[4] A. Terán, F. Casafont, E. Fábrega, V. M. Martı́nez-Taboada, V.
Rodrı́guez-Valverde, and F. Pons-Romero, “Adult-onset Still’s
disease with liver failure requiring liver transplantation,” Gastroenterologı́a y Hepatologı́a, vol. 32, no. 10, pp. 681–686, 2009
(Spanish).
[5] F. S. Taccone, V. Lucidi, V. Donckier, N. Bourgeois, G. Decaux,
and F. Vandergheynst, “Fulminant hepatitis requiring MARS
and liver transplantation in a patient with Still’s disease,”
European Journal of Internal Medicine, vol. 19, no. 6, pp. e26–
e28, 2008.
[6] M. Mcfarlane, M. Harth, and W. J. Wall, “Liver transplant in
adult Still’s disease,” The Journal of Rheumatology, vol. 24, no.
10, pp. 2038–2041, 1997.

Case Reports in Medicine
[7] J. Yamanaka, S. Saito, N. Kuroda, T. Hirano, and J. Fujimoto,
“Successful living related liver transplantation for adult Still’s
disease,” Journal of Gastroenterology and Hepatology, vol. 18, no.
9, pp. 1109–1110, 2003.
[8] A. Ogata, M. Kitano, J. Yamanaka et al., “Interleukin 18 and
hepatocyte growth factor in fulminant hepatic failure of adult
onset Still’s disease,” The Journal of Rheumatology, vol. 30, no. 5,
pp. 1093–1096, 2003.
[9] O. Dino, G. Provenzano, G. Giannuoli, E. Sciarrino, M. Pouyet,
and L. Pagliaro, “Fulminant hepatic failure in adult onset Still’s
disease,” The Journal of Rheumatology, vol. 23, no. 4, pp. 784–
785, 1996.
[10] E. G. Bywaters, “Still’s disease in the adult,” Annals of the
Rheumatic Diseases, vol. 30, no. 2, pp. 121–133, 1971.
[11] G. Magadur-Joly, E. Billaud, J. H. Barrier et al., “Epidemiology of
adult Still’s disease: estimate of the incidence by a retrospective
study in west France,” Annals of the Rheumatic Diseases, vol. 54,
no. 7, pp. 587–590, 1995.
[12] K. Wakai, A. Ohta, A. Tamakoshi et al., “Estimated prevalence
and incidence of adult Still’s disease: findings by a nationwide
epidemiological survey in Japan,” Journal of Epidemiology, vol.
7, no. 4, pp. 221–225, 1997.
[13] M. M. Thabah, K. K. Singh, S. M. Madhavan, and R. Gupta,
“Adult onset Still’s disease as a cause of acute liver failure,”
Tropical Gastroenterology, vol. 29, no. 1, pp. 35–36, 2008.
[14] S. J. Ott, A. Baron, T. Berghaus, R. Lamerz, and U. Beuers, “Liver
failure in adult Still’s disease during corticosteroid treatment,”
European Journal of Gastroenterology & Hepatology, vol. 15, no.
1, pp. 87–90, 2003.
[15] B. Linde, P. Oelzner, K. Katenkamp, G. Hein, and G. Wolf,
“Fulminate liver failure in a 39-year-old female patient with
leukocytosis, unclear fever, and arthralgic pain,” Medizinische
Klinik, vol. 102, no. 10, pp. 846–851, 2007 (German).
[16] E. Mylona, S. Golfinopoulou, M. Samarkos, P. Fanourgiakis,
V. Papadakos, and A. Skoutelis, “Acute hepatitis in adult Still’s
disease during corticosteroid treatment successfully treated
with anakinra,” Clinical Rheumatology, vol. 27, no. 5, pp. 659–
661, 2008.
[17] T. Nagashima, Y. Aoki, S. Onishi, M. Iwamoto, H. Okazaki,
and S. Minota, “Steroid-refractory severe hepatic failure in
adult onset Still’s disease responding to cyclosporine,” Clinical
Rheumatology, vol. 27, no. 11, pp. 1451–1453, 2008.
[18] T. Hogan, K. T. Kao, and J. Tung, “A rare case of severe acute
hepatitis associated with adult-onset Still disease dramatically
improved by high-dose steroid therapy,” Gastroenterology &
Hepatology, vol. 7, no. 12, pp. 841–844, 2011.
[19] A. Takami, S. Nakao, H. Miyamori et al., “Adult-onset Still’s
disease with submassive hepatic necrosis,” Internal Medicine,
vol. 34, no. 2, pp. 89–91, 1995.
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